Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23, Morning
The Evolution and Beyond of NewCo Session
Stay tuned
Planners
Jielun Zhu: Partner, NewCo Capital
Jie Wu: Head of Asia Pacific, MPM BioImpact / CBO, K2
Recent Trends and Future Outlook of NewCo Transactions
Eric Liu: Locust Walk China Head
Key Decisions in the Third Generation Evolution of NewCos and What Lies Ahead
Bella Chen: Partner, JunHe LLP
TBD
王宁玲: Managing Partner, Shanghai Office of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Roundtable 1: Review, Iteration, and Evolution of the NewCo Model
Jie Wu (Moderator): Head of APAC, MPM BioImpact
Howard Liang: Ex-CFO & Chief Strategy Officer of BeOne (BeiGene); Ex-CFO & President of Tessera Therapeutics
Weidong Liu: Managing Director, Vivo Capital
Mark Tang: Chairman, World Biotech Capital LLC
Pony: CEO & Executive Director, VISEN Pharmaceuticals
Roundtable 2: NewCo's Exit and Related Challenges
Jielun Zhu (Moderator): Partner, NewCo Capital
Nisa Leung: Managing Partner, Aulis Capital
Zhui Chen: Founder and CEO, OTR Therapeutics
Hua Jiang: Executive Director, External Innovation & Partnership, BeOne
Ke Geng: Partner, O'Melveny & Myers
July 23, 15:30–17:30
Cross-border Investment Session
Stay tuned
15:20-15:35 Cross-borderM&A of Pharmaceutical Assets:Structures, Trends and Challenges
Frank Zhou: Partner, JunHeLLP
15:35-15:50 Offshore Listings of Biotech Companies - Key Considerations
Ke Geng: Ph.D., Managing Partner、Member of the Firm's Policy Committee
15:50-16:05 Global Life Sciences Transactions and the Outbound Expansion of Chinese Innovative Drugs
Daniel Mathews:EY Global Life Sciences Sector Partner
16:05-16:40 Roundtable: Cross-Border Investment and Industrial Transactions of Innovative Drugs
Winnie Wang (Moderator): Partner, Pacific Bridge NY Fund
Yongling Shi: Partner, MING BIOVENTURES
Quan Fu: Partner, TTM Capital
Yunlong Song: Founder、CEO,Shanghai Cloudthera Bioscience Ltd.
Yingjie Wu: Executive Director, Search & Evaluate, Business Development, Oncology R&D, AstraZeneca
Yu Zeng: Founder, Teal Rise Capital
16:40-17:30 Insight Dialogue: AI-driven Paradigm for China Biotech Innovation Globalization
Tony Zhang, Ph.D., MBA (Moderator): CEO & Co-founder, BridgeBio Global
Tom Du, Ph.D.: Founder & Chairman, Evergreen Therapeutics
Bin Xiao, Ph.D., M.D.: Co-Founder & Chief Scientific Officer, Uni-Pioneers BioMed (UP-Bio)
Stanley Lau: CEO & Founder, Tailai Biosciences
Peter Zhang, EMBA: ex-Head of Strategy and Commercial Excellence & Operations, Biogen China